Delee on Republic

Blood testing device for early diagnosis of cancer and treatment monitoring

Raise to date: $911,701

Reporting Date: 04/05/2020

Key Stats

Minimum Raise

$75,000

Maximum Raise

$1,070,000

Likelihood of Max Likely
Start Date

12/11/2019

Stop Date

04/24/2020

Days Remaining

17

Security Type

SAFE

Investment Minimum

$50

Deal Type

Deal to Watch


Investment Summary

Status

Active

# of Investors

3,939

% of Minimum Raised

1,216%

% of Maximum Raised

85%

Dollars Per Day to Reach Max

$9,312

DPD* Committed

$7,859

DPD* Category

$0

DPD* All Companies

$917

Kingscrowd Momentum

$911,701

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Delee, with a valuation cap of $10 million, is raising funds on Republic. The company has created a device, CytoCatch, for the early detection of circulating tumor cells in the bloodstream. The device also assists in the personalization and optimization of the treatment of patients and monitor the effectiveness of treatments. Thus, CytoCatch helps to increase the chances of curing cancer and survival. Delee was founded by Liza Velarde, Juan Felipe Yee, and Alejandro Abarca in November 2016 and has already raised over $1.3 million in funding since its inception. The current round of crowdfunding has a minimum goal of $75,000 and a maximum goal of $1,070,000. Delee already has a fully functional technology that is being tested for prostate cancer.

INVEST NOW